-transparent.png){kind=logo}
Plasma levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein I (IGFBP-I) were measured in fasting blood samples obtained from 16 postmenopausal breast cancer patients before and during tamoxifen treatment for 1 to 6 months. Tamoxifen suppressed total plasma IGF-I by a mean of 28.5% (P less than 0.001) but elevated plasma IGFBP-I by a mean value of 78% (P less than 0.001). Changes in plasma levels of growth hormone, insulin, or insulin C-peptide were not observed. These findings suggest that tamoxifen exerts its influence on plasma IGF-I and IGFBP-I by mechanisms other than those known to regulate the plasma levels of these peptides, primarily growth hormone and insulin, respectively. A dual effect suppressing plasma IGF-I and elevating plasma IGFBP-I suggests that tamoxifen may have a significant influence on endocrine and possibly paracrine delivery of IGF-I to breast cancer cells in vivo.
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
April 1989,
Cancer research,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
September 2005,
Urology,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
January 2005,
Biological trace element research,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
January 1999,
International journal of surgical investigation,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
July 1994,
Cancer,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
December 2013,
Breast (Edinburgh, Scotland),
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
October 1993,
Cancer research,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
November 2003,
ANZ journal of surgery,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
November 1998,
British journal of rheumatology,
P E Lønning, and
K Hall, and
A Aakvaag, and
E A Lien
September 2002,
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
